When Aardvark Therapeutics announced earlier this month that it was pausing a phase 3 trial of its lead metabolic candidate, ...

Gilead Sciences is paying $1.67 billion for a T-cell engager (TCE) company via a front-loaded deal that could also give new meaning to its partner Galapagos. By acquiring GSK-founded Ouro Medicines, ...

Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its ...

Sanofi has returned to T-cell engager (TCE) territory via an agreement to pay $180 million in the near term for a phase ...

Qatar’s exports of natural gas and helium—the latter essential for MRI scans—were effectively halted after Iran closed the Strait of Hormuz and attacked one of the world’s largest production ...

Last year’s funding cuts at the National Institutes of Health (NIH) disproportionately impacted women and early-career ...

Apogee Therapeutics has published phase 2 eczema data that suggest its anti-IL-13 antibody is a threat to Eli Lilly, ...

Stryker continues to dig itself out of the hole left by the global cyberattack it suffered nearly two weeks ago, saying its ...

When Ron Cohen, M.D., CEO of Oryon Cell Therapies, recently dug into the company’s Parkinson’s disease data, he told Fierce ...

In this episode of The Top Line, Olive McCormick joins host Chris Hayden to examine one of the most overlooked risks in ...

Health authorities in the U.S. are continuing their move away from animal testing in drug development, with the FDA signaling ...

Swiss pharma Roche is staying in lockstep with Eli Lilly, expanding its artificial intelligence offerings and Nvidia ...